Passaro, AAPassaroWang J.Wang, YYWangLee, S-HS-HLeeMelosky, BBMeloskyJIN-YUAN SHIHAzuma, KKAzumaJuan-Vidal, OOJuan-VidalCobo, MMCoboFelip, EEFelipGirard, NNGirardCortot, A BA BCortotCalifano, RRCalifanoCappuzzo, FFCappuzzoOwen, SSOwenPopat, SSPopatTan, J-LJ-LTanSalinas, JJSalinasTomasini, PPTomasiniGentzler, R DR DGentzlerWilliam, W NW NWilliamReckamp, K LK LReckampTakahashi, TTTakahashiGanguly, SSGangulyKowalski, D MD MKowalskiBearz, AABearzMacKean, MMMacKeanBarala, PPBaralaBourla, A BA BBourlaGirvin, AAGirvinGreger, JJGregerMillington, DDMillingtonWithelder, MMWithelderXie, JJXieSun, TTSunShah, SSShahDiorio, BBDiorioKnoblauch, R ER EKnoblauchBauml, J MJ MBaumlCampelo, R GR GCampeloCho, B CB CCho2024-02-232024-02-232024-0109237534https://scholars.lib.ntu.edu.tw/handle/123456789/639920Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial.enEGFR-mutated; NSCLC; amivantamab; lazertinib; post-osimertinibAmivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyjournal article10.1016/j.annonc.2023.10.117378794442-s2.0-85175640787https://api.elsevier.com/content/abstract/scopus_id/85175640787